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Cutaneous T-cell lymphoma (CTCL) is
acknowledged to be a neoplastic pro-
cess with clonal malignant T cells that
can metastasize to regional lymph
nodes and, occasionally, to visceral
organs (Hwang et al., 2008). Similar to
other solid tumors, large, bulky CTCL
tumors can be both disfiguring as well
as serve as portals for infection if they
begin to ulcerate. Moreover, in contrast,
CTCL cells are immune cells them-
selves, often originate from CD4þ T
cells in mycosis fungoides (the most
common form of CTCL) and respond
to immunomodulatory agents such
as corticosteroids and imiquimod
(Dummer et al., 2003). CTCL tumors
develop in a complex immunological
environment that comprises macro-
phages, dendritic cells, innate immune
cells, and other T cells (Kim et al.,
2005). Recent clinical data suggest that
the presence of certain immune cells
(i.e., CD8þ T cells) in the skin can
correlate with a better prognosis in
CTCL and that others (i.e., macro-
phages) correlate with a poor prognosis
(Sugaya et al., 2012).
Our recent work has focused on the
role of macrophages in a unique murine
model of CTCL (Wu et al., 2011; Wu
et al., 2014). In this model, we inject
MBL2 T lymphoma cells into the
ear skin of wild-type C56BL/6 mice
(Figure 1). Skin lymphoma tumors only
occur if a well-known contact sensitizer,
di-nitro-fluoro-benzene (DNFB), is topi-
cally applied to skin immediately after
inoculation of MBL2 T cells into skin.
We have shown that even a single
application of DNFB results in activa-
tion of IL-1b in the skin and that recom-
binant IL-1b can partially replace DNFB
treatment as an enabler of tumor growth
in this model (Wu et al., 2011). Of note,
corticosteroids, well known to be first-
line treatment for human mycosis
fungoides, block the development of
tumors in this murine model. F4/80þ
macrophages and Gr-1þ neutrophils
are the predominant immune cell popu-
lations that infiltrate the tumor over the
2 weeks that are required for tumor
formation. Interestingly, depletion of
neutrophils using anti-Gr-1 antibodies
has no effect on tumor development
(Wu et al., 2011). Using an agent,
clodronate liposomes, that depletes
(kills) phagocytic cells such as macro-
phages in skin, however, we show that
tumor formation is nearly completely
blocked by clodronate treatment.
This result suggests that macrophages,
or possibly other phagocytic cells,
have a key role in supporting tumor
development.
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Figure 1. An inflammation-dependent model of skin T-cell lymphoma tumorigenesis. MBL2 T lymphoma cells are inoculated in the ear skin of wild-type C57BL/6
mice and then immediately treated with di-nitro-fluoro-benzene, a well-established contact sensitizer. Histologically high-grade tumors form in DNFB-treated ears
within 14 days (adapted from (Wu et al., 2011)).
1Department of Dermatology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA
Correspondence: Sam T. Hwang, MD, PhD, E4100 Froedtert Hospital, 9200 W. Wisconsin Avenue, Milwaukee, Wisconsin 53226, USA. E-mail: sthwang@mcw.edu
34 The Journal of Investigative Dermatology Symposium (2015), Volume 17 & 2015 The Society for Investigative Dermatology
We have extended our work to show
that human CTCL tumors derived from
Hut78 cells are also sensitive to clodro-
nate liposome treatment (Wu et al.,
2014). Examination of clodronate lipo-
some-treated tumors revealed decreased
expression of angiogenic markers and
signaling pathways (i.e., STAT3) that
have been implicated in human CTCL
tumors. Furthermore, we can show that
the macrophages found in CTCL tumors
are of the M2 phenotype that have been
implicated as being protumorigenic in
solid cancers (Mantovani et al., 2010).
These data provide additional experi-
mental support for recent clinical
observations from Hodgkin’s disease
and in CTCL that suggest a key role for
CD63þ macrophages in supporting
lymphomagenesis (Steidl et al., 2010;
Sugaya et al., 2012).
Interestingly, clodronate liposomes
are not toxic to MBL2 T cells in vitro,
suggesting the possibility of a therapeu-
tic strategy-based regulation of the
immune environment. Understanding
the fundamental roles of macrophages
in tumor development may aid us in
developing more effective therapies
for CTCL in which we regulate the
immune environment instead of directly
killing the neoplastic cell, which has
been the traditional goal of cytotoxic
chemotherapy.
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